OverviewSuggest Edit

Innovating Women’s Reproductive Health and Pregnancy Therapeutics ObsEva is a biopharmaceutical company innovating women’s reproductive health and pregnancy therapeutics from conception to birth. Between the ages of 20 and 50, millions of women worldwide suffer from reproductive health conditions that affect their quality of life and their ability to conceive or may lead to complications during pregnancy. ObsEva aims to improve upon the current treatment landscape with the development of novel, oral medicines with potentially best-in-class safety and efficacy profiles. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with multiple development programs focused on treating endometriosis, uterine fibroids, and preterm labor. ObsEva is supported by top-tier investors and a globally recognized board and is well-positioned to establish a leadership position in women’s reproductive therapeutics.
TypePrivate
Founded2012
HQPlan-les-Ouates, CH
Websiteobseva.com

Latest Updates

Employees (est.) (Sep 2019)52(-1%)

Key People/Management at ObsEva

Ernest Loumaye

Ernest Loumaye

Co-Founder & CEO

ObsEva Office Locations

ObsEva has an office in Plan-les-Ouates
Plan-les-Ouates, CH (HQ)
1228 Plan-les-Ouates
Show all (1)

ObsEva Financials and Metrics

Summary Metrics

Founding Date

2012

ObsEva total Funding

$92.9 m

ObsEva latest funding size

$60 m

Time since last funding

4 years ago

ObsEva investors

ObsEva's latest funding round in November 2015 was reported to be $60 m. In total, ObsEva has raised $92.9 m
Show all financial metrics

ObsEva Online and Social Media Presence

Embed Graph

ObsEva News and Updates

ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF

Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation

ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban

                                        

ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City

Geneva, Switzerland and Boston, MA – July 12, 2019– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that the…

ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids

Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today report…

ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna

Geneva, Switzerland and Boston, MA – June 21, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today annou…
Show more

ObsEva Blogs

ObsEva announces new composition of its Executive Committee

Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage... The post ObsEva announces new composition of its Executive Committee appeared first on ObsEva.

ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 13- 14, 2019

Geneva, Switzerland and Boston, MA – August 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical... The post ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 13- 14, 2019 appeared first on ObsEva.

ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC

Geneva, Switzerland and Boston, MA – August 7, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage... The post ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC appeared first on ObsEva.

ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019

Geneva, Switzerland and Boston, MA – August 5, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage... The post ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019 appeared first on ObsEva.

Work With Us

Are you ready to join an innovative biopharmaceutical company that’s advancing women’s reproductive health and pregnancy therapeutics? Explore our available... The post Work With Us appeared first on ObsEva.

ObsEva Frequently Asked Questions

  • When was ObsEva founded?

    ObsEva was founded in 2012.

  • Who are ObsEva key executives?

    ObsEva's key executives are Ernest Loumaye.

  • How many employees does ObsEva have?

    ObsEva has 52 employees.

  • Who are ObsEva competitors?

    Competitors of ObsEva include BTG, Zogenix and Clinigen Group.

  • Where is ObsEva headquarters?

    ObsEva headquarters is located at 1228 Plan-les-Ouates, Plan-les-Ouates.

  • Where are ObsEva offices?

    ObsEva has an office in Plan-les-Ouates.

  • How many offices does ObsEva have?

    ObsEva has 1 office.